Professor Pu Xiaoyong: Guidelines are empowered, far and stable, CUA and CSCO jointly create a new pattern of prostate cancer diagnosis and treatment

Deputy Chief Physician of Department of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Doctor of Medicine, Postdoctoral Fellow, Master Supervisor, Secretary of the Ninth Branch of Surgery, Deputy Director of Administration

Visiting scholar at Beth Israel Medical Center, USA

Vice Chairman of Andrology Branch of Guangdong Medical Association

Vice Chairman of Urology Branch of Guangdong Medical Industry Association

Vice President of Urological Health Branch of Guangdong Health Association

Deputy leader of the Robotics Group of the Urology Branch of Guangdong Medical Association

Deputy leader of the Microminimally Invasive Surgery Group of Andrology Branch of Guangdong Medical Association

Member of the Standing Committee of the Urology Branch of Guangdong Medical Association

Member of the Urology andrology Engineering Group of the Urology Branch of the Chinese Medical Association

Member of Prostate Cancer Collaborative Group of Urologists Branch of Chinese Medical Doctor Association

Member of the Chemical Transfer Group of the Urologist Branch of the Chinese Medical Doctor Association

Member of the first committee of the Andrologist Self-discipline and Rights Protection Expert Committee of the Andrologist Branch of the Chinese Medical Doctor Association

The first member of the Precision Medicine Group of the Urogenital Tumor Committee of the Chinese Anti-Cancer Association (CACA-GU).

Member of Evidence-Based Medicine Branch of China Association for the Promotion of International Exchanges in Healthcare

Member of the Rapid Rehabilitation Group of the Urology Professional Committee of the Chinese Research Hospital Association

Member of the first session of the Professional Committee on Sexual Dysfunction of the Asian Andrology Association

Member of the first and second sessions of the Sexual Medicine Branch of Guangdong Medical Association

Member of the Urology Professional Committee of Guangdong Association of Integrative Medicine

Member of the Standing Committee of the Genitourinary Oncology Professional Committee of Guangdong Anti-Cancer Association

Member of the Standing Committee of Men's Health Management Committee of Guangdong Health Management Association

Standing Committee Member of Urologic Oncology Branch of Guangdong Genitourinary Association

Standing member of the Urine Control Branch of Guangdong Genitourinary Association

Member of the Minimally Invasive Surgery Professional Committee of Guangdong Association of Integrative Medicine

Member of Urolaparoscopy Branch of Guangdong Genitourinary Association

Member of Precision Medicine Branch of Guangdong Genitourinary Association

Member of Urology Professional Committee of Guangdong Medical Education Association

Member of the Urological Oncology Group of the Urology and Andrology Professional Committee of Guangdong Health Management Association

Member of the Multidisciplinary Collaborative Group of Prostate Cancer of the Genitourinary Tumor Professional Committee of Guangdong Anti-Cancer Association

CUA and CSCO work together to move forward together

Behind each clinical diagnosis and treatment guide and consensus is the wisdom and painstaking efforts of the most authoritative experts in various fields, and the guide simplifies the complexity and provides clinicians with the best quality diagnosis and treatment guidance and suggestions
.
The continuous update of CSCO and CUA guidelines has injected new impetus
into the prosperity and development of urology in China.

Professor Pu mentioned that the CSCO and CUA guidelines are slightly different
in terms of organizational structure and development focus.
CUA is the first academic group of urology in New China established by Academician Wu Jieping in 1981, as the earliest and most authoritative academic society in urology in China, CUA guidelines are updated every few years, focusing on multi-center prospective high-quality studies of clinical research data of Chinese patients, and are committed to exploring the clinical characteristics
of prostate cancer in China.
CSCO is a professional academic group voluntarily formed by clinical oncologists, and the CSCO guidelines are updated every year, paying more attention to the latest global research results, summarizing the field of prostate cancer research, and making important reference tips
for its clinical work.

Professor Pu believes that although the CUA and CSCO guidelines are not legal documents and are not legally binding, they enable clinicians to carry out diagnosis and treatment activities
in a more standardized manner.
Professor Pu pointed out that due to the uneven economic level of patients and medical resources in different regions, clinicians need to follow the treatment principles of guidelines and choose the best treatment decision
according to the characteristics of patients.
It is worth noting that with the increasing update and continuous change of medical evidence and research, there is often a certain lag in the update of guidelines, and for patients whose clinical conditions exceed the guidelines, doctors need to combine their own experience, patient treatment effects, and the latest research results to improve patient benefits as the fundamental requirement, and implement diagnosis and treatment plans
that exceed the guidelines as appropriate.

Optimize diagnosis and treatment methods to help the development of diagnosis and treatment

The continuous breakthrough in the field of prostate cancer diagnosis and treatment, the industry has overcome difficulties, enriched treatment methods, developed and applied innovative drugs, completed the whole management process, etc.
, and kept pace with the times and forged ahead, which has led to major changes
in the treatment pattern of prostate cancer.

From the perspective of CUA and CSCO guidelines, Professor Pu noted the following changes:

First, screening of high-risk populations is critical
to improving prostate cancer cure rates.
With the development of science and technology to empower medical treatment, diagnostic technologies such as liquid biopsy, new MRI, PSMA PET/CT and other diagnostic technologies have effectively improved the detection rate and diagnostic accuracy
of prostate cancer.

Secondly, the emergence of da Vinci robot is a milestone in the history of prostate cancer surgery, and through robot technology, the "three consecutive victories"
of radical prostatectomy can be achieved.

Finally, new drugs emerge one after another, strongly reversing patient survival
.
It is now recognized that genetic testing can inform treatment decisions for prostate cancer, and PARP inhibitors or taxaneous chemotherapy drugs can be given to patients with mutations in the DNA repair genes BRCA1, BRCA2 or AR-V7
.
At the same time, new endocrine therapies such as enzalutamide and apatamide also provide new treatment options for castration-resistant prostate cancer patients, making them achieve more positive clinical treatment outcomes
.

Cultivate fertile soil for the growth of "society" and cultivate first-class medical talents

Healthy China, urology first
.
With the joint efforts of several generations of urologists, China's urology industry has developed rapidly in the past 40 years, and great breakthroughs
have been made in many aspects such as the diagnosis and treatment concept of urological diseases, surgical technology, and basic scientific research.

Talking about the increasing number of brand academic conferences and continuously injecting fresh vitality into the development of urology in China, Professor Pu believes that CUA and CSCO shoulder the important mission
of academic leadership.
Today's echelon is tomorrow's backbone, and if Chinese urology wants to realize the vision of "leading in Asia and world-class", it must build a high-quality talent team
.
For example, China's urology "general talent project", Chinese experts can learn foreign advanced professional knowledge and exquisite surgical technology
through overseas training.
Similarly, once the "CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer (2022 Edition)" was released, CSCO organized experts to conduct a number of tours across the country, which systematically improved the comprehensive ability and practical operation ability
of urologists.

Specializing in training young and middle-aged doctors to help the "Healthy China" to further promote
.
Professor Pu believes that we should treat learning with the attitude of "those who know are not as good as those who are good, and those who are good are not as good as those who are happy", truly regard learning as a pursuit, a hobby, and a healthy lifestyle, and encourage young doctors to actively participate in the activities of the society, integrate and use the databases of major alliances, carry out high-quality real-world research and multi-center clinical research, and continuously promote the continuous progress
in the field of urologic tumors.

Expert Talk

Both CUA and CSCO guidelines are based on Chinese clinical practice, adhere to reform and innovation, keep pace with the times, and provide scientific and comprehensive decision-making recommendations
for the majority of urologists.
It is hoped that the majority of colleagues can make full use of these two platforms, and hope that these two guidelines can continue to provide reference and basis for the clinical work of urologists, and further promote the diagnosis and treatment of prostate cancer in China to a higher level
.

Past Review